Ernexa Therapeutics Inc. Warrants

ERNA

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US6 employeesernexatx.com

$0.20

-0.01(-3.14%)

Mkt Cap $2M

$0.19

$3.72

52-Week Range

At a Glance

AI-generated

Ernexa Therapeutics Inc.

$2M

Market Cap

—

Revenue

-$14M

Net Income

Employees6

Fundamentals

How The Business Makes Money

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Material Agreement

Feb 10, 2026

Entry into a Material Definitive Agreement. On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agen

Regulation FD

Feb 25, 2026

, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (t

Company Profile

CIK0000748592

ISINUS1140823089

CUSIP114082308

Phone212 582 1199

Address10355 Science Center Drive, Cambridge, MA, 92121, US

SEC EDGAR